Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Motohiro Soejima

Tatsuya Yoshiuchi

Shigeki Hibi

Yoshinori Takahashi

Hisashi Shibata

Yorihisa Hoshino

Kogyoku Shin

Norihito Ohi

Tetsuya Hirakawa

Seiichi Kobayashi

Kouichi Kikuchi

Koichi Kikuchi

Mitsuhiro Ino

Mutsuko Ono

Toshihiko Kaneko

Mitsuaki Miyamoto

Nobuaki Sato

Takashi Doko

Taro Terauchi

Koji Yamada

Katsuhiro Moriya

Yoshinori Sakuma

Keizo Sato

Mark Spyvee

Kenzo Muramoto

Makoto Okita

Hitoshi Oinuma

Ieharu Hishinuma

Heather Davis

Boris M Seletsky

Yimin Jiang

Wanjun Zheng

André Lescarbeau

Xiang-Yi Li

Bruce Decosta

Fabian Gusovsky

Masayuki Tanaka

Hiromitsu Yokohama

Makoto Kaino

Marc Pesant

Koichi Katayama

Kokichi Harada

Ye Yao

Hidenori Seshimo

Naohiro Kohmura

Yukio Nishizawa

Mutsuko Tabata

Lynda Tremblay

Yan (Janet) Zhao

Jane Daun

Jose Luis Castro Pineiro

Afzal Khan

Alan James Braunton

Andrew Payne

Louise Michelle Birch

James Edward Kitulagoda

Hiroyuki Yoshimura

Fumihiro Ozaki

Takashi Sato

Takayuki Hida

Yoshihiko Norimine

Eriko Doi

Noboru Yamamoto

Takafumi Motoki

Yoshimitsu Naoe

Tasuku Ishida

Kiyoaki Kobayashi

Daiju Hasegawa

Shigeru Akasofu

Nobuyuki Kurusu

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

4-azaindole derivatives

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R, Rand Rrepresent hydrogen, etc., Xrepresents Calkylene, etc., Xrepresents Calkylene, etc., Arepresents a 5- to 6-membered heterocyclic group, etc., and Arepresents Caryl, etc.

Bicycloamine derivatives

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.  Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

[object Object]

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein Rdenotes a hydrogen atom, a Calkyl group, a Calkoxy group and the like; Rdenotes a halogen atom, a cyano group, a nitro group, a Calkyl group, a Calkenyl group, Calkynyl group and the like; Rdenotes a Caromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR(wherein Rdenotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated Calkyl group and the like) and, in this case, at least two of X, Y and Z denote CR.

Imidazo[1,2-b]pyridazine compound

Compounds represented by the general formula: [wherein Rrepresents methoxy, ethyl, methylthio, etc., R, Rand Reach represent hydrogen, a halogen, etc., Rand Reach represent &#x2014;X&#x2014;X&#x2014;X(wherein Xrepresents a single bond or &#x2014;CO&#x2014;, Xrepresents a single bond, &#x2014;NR, etc. and Xand Reach represent hydrogen, Calkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.

Pyrazolo[1,5-a]pyridines and medicines containing the same

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

1H-indazole compounds

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Rdesignates &#x2014;(CO)&#x2014;(NR)&#x2014;(CR&#x2550;CR)&#x2014;Ar (wherein R, Rand Reach independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted Calkyl group or the like;

Pyrazole compound and medicinal composition containing the same

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Pyrazolo[1,5-a] pyridines and medicines containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

Growing community of inventors

Tsukuba, Japan

Motohiro Soejima